Charles River Laboratories International, Inc. (CRL)
Health Care · Life Sciences Tools & Services · US stock · S&P 500 component
$300.15
▼ -6.09 (1.99%)
Fair valueOvervalued
$169 −43.8% to fair value
$84fair band $118–$219$253
Day's range
$296.35 – $308.83
52-week range
$146.20 – $333.30
About Charles River Laboratories International, Inc.
Charles River Laboratories supports drug development with research models, preclinical services and manufacturing support. It breeds laboratory research animals, carries out discovery and safety assessment studies for drug candidates, and supplies testing and related services for the manufacture of biologic products. Customers are pharmaceutical and biotechnology companies, along with academic and government researchers. The business is organised into groups for research models, discovery and safety assessment, and manufacturing solutions.
Revenue of $4.0 billion over the last twelve months comes from research models and from fees for contract research and testing work. Revenue has grown at 0.3% a year across the last three years. The operating margin is 2.3%, the business earns 1% on the capital invested in it, and net debt is 6.3 times EBITDA. No dividend is paid. On the site's X-Ray Score it receives 22 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $146.20 – $333.30Volume 674,600Daily, split-adjusted
Vitals
Market cap$14.4B
52-week range$146.20 – $333.30
Volume (last day)674,600
P/E (TTM)–
EBIT / EV yield0.5%
Free-cash-flow yield2.6%
Dividend yieldNo dividend
Revenue (TTM)$4.0B
Net income (TTM)−$238M
Operating margin2.3%
Return on capital1.4%
Debt incl. leases$2.6B
Cash & securities$192M
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$169model spread $169 – $169
Overvalued
−43.8% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $300
Undervalued < $118Fair $118 – $219Overvalued > $219
10-year DCF (market-scaled)
$-57
Peer multiples
$169
Earnings power floor (not blended)
$25
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Weak business, priced high
Our models put fair value below today's price, so a lot of good news may already be in the price. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Weak
15/100
Expensive against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield0.5%
Free-cash-flow yield2.6%
Fair value vs price0.6×
Growth
Weak
23/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)0.3%
Growth consistency20%
Profitability
Weak
33/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital1.4%
Operating margin2.3%
Financial health
Weak
14/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score4 / 9
Net debt / EBITDA6.3×
Interest cover0.8×
Dividends
None
–/100
Pays no dividend.
See the numbers →
Quarterly results: last 6 quarters
-2.7%
Mar '25
+0.6%
Jun '25
-0.5%
Sep '25
-0.8%
Dec '25
+1.2%
Mar '26
-2.7%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $1.0B, diluted EPS $-0.03.
Compare with peers
MTD Mettler Toledo Interna...50 A Agilent Technologies,...42 IQV Iqvia Holdings Inc.42 TECH BIO-TECHNE Corp40Other Life Sciences Tools & Services companies by X-Ray Score.
Fundamentals checklist
● 2 Good · ● 1 Average · ● 11 BadCash quality
Earnings backed by cashGood
Free-cash-flow yieldBad
Risk models
Altman Z''Bad
Piotroski F-ScoreBad
Growth
Free-cash-flow growth (3y)Good
Revenue growth (3y)Bad
Growth consistencyBad
Balance sheet
Current ratioAverage
Net debt / EBITDABad
Interest coverBad
Valuation
Fair value vs priceBad
EBIT / EV yieldBad
Profitability
Return on invested capitalBad
Operating marginBad
Each check is graded against the company's sector, not a fixed number. Checklist score 24/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $3.5B | $4.0B | $4.1B | $4.0B | $4.0B |
| Operating income | $590M | $651M | $617M | $227M | $25M |
| Net income | $391M | $486M | $475M | $22M | −$144M |
| Operating cash flow | $761M | $620M | $684M | $735M | $738M |
| Operating margin | 16.7% | 16.4% | 14.9% | 5.6% | 0.6% |
| Free cash flow | $532M | $295M | $365M | $502M | $518M |
| Diluted EPS | $7.60 | $9.48 | $9.22 | $0.20 | $-2.91 |
Fiscal years, from SEC filings.
Technical summary
Daily
Bullish
10 bullish · 4 neutral · 2 bearish
Weekly
Strongly bullish
11 bullish · 0 neutral · 1 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 302.5 | Bearish |
| EMA 10 | 300.3 | Bearish |
| SMA 20 | 295.8 | Bullish |
| EMA 20 | 296.3 | Bullish |
| SMA 50 | 288.9 | Bullish |
| EMA 50 | 281.9 | Bullish |
| SMA 100 | 250.3 | Bullish |
| EMA 100 | 257.7 | Bullish |
| SMA 200 | 215.1 | Bullish |
| EMA 200 | 229.3 | Bullish |
Oscillators (daily)
| RSI (14) | 55.56 | Neutral |
| MACD (12, 26) | 5.75 | Bullish |
| Momentum (12) | 1.74 | Bullish |
| Stochastic %K (14) | 31.92 | Neutral |
| Williams %R (14) | -68.08 | Neutral |
| CCI (20) | 61.74 | Neutral |
Pivot points (classic, last session)
S3 282.2 | S2 289.3 | S1 294.7 | Pivot 301.8 | R1 307.2 | R2 314.3 | R3 319.7 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
CRL SEC filings
24 Sep 2026
8-KSEC EDGAR
Regulation FD disclosure
5 Aug 2026
10-QSEC EDGAR
Quarterly report
5 Aug 2026
8-KSEC EDGAR
Results of operations
11 May 2026
8-KSEC EDGAR
Director or officer change; Shareholder vote results
7 May 2026
10-QSEC EDGAR
Quarterly report
7 May 2026
8-KSEC EDGAR
Results of operations
31 Mar 2026
DEF 14ASEC EDGAR
Proxy statement
25 Feb 2026
8-KSEC EDGAR
Regulation FD disclosure
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.